Weill Cornell has an internationally recognized clinical and translational research program for acute and chronic leukemias, myelodysplastic syndrome and myeloproliferative disorders. Our centers for lymphoma and myeloma house the country’s largest clinical research programs focused on novel therapies for the treatment of these blood cancers.
Weill Cornell has an internationally recognized clinical and translational research program for acute and chronic leukemias, myelodysplastic syndrome and myeloproliferative disorders. In affiliation with NewYork-Presbyterian Hospital, the Meyer Cancer Center offers unparalleled inpatient and outpatient care with resources designed to address the very special needs of patients and our doctors work closely with specialists in infectious diseases, geriatrics, critical care, cardiology, gastroenterology and other medical subspecialities to provide comprehensive care. They also have access to exciting novel drugs and clinical trials in these areas.
The Center for Lymphoma houses one of the country’s largest clinical research programs focused on novel therapies for this diverse group of more than 60 related cancers including chronic lymphocytic leukemia (CLL) and Waldenstrom’s Macroglobulinemia. Our physicians were among the first to treat lymphoma with a combination of monoclonal antibodies targeting two different molecules on the surface of lymphoma cells. We have contributed to the development of the vast majority of FDA approved lymphoid cancer therapies and are continually offering trials with the most promising novel agents under study. Clinical research and care are enhanced by one of the country’s most respected hematopathology programs, as well as radiology programs that have helped to define the optimal role of imaging studies in the assessment and management of lymphoma.
The Center for Myeloma is a clinical and research center of excellence dedicated to providing individualized comprehensive diagnostic and therapeutic approaches to all patients with myeloma and related disorders. Special programs include anti-angiogenic therapy of myeloma, radioactive antibody therapies, new chemotherapy drugs, vaccine therapies, and basic research into the cause of myeloma.
The Pediatric Hematology and Oncology Program at Weill Cornell Medical College/NewYork-Presbyterian is a leading center for the treatment of cancer and blood disorders in children. It has broad expertise in the treatment of children and adolescents with a variety of blood disorders, both malignant and non-malignant, with four specialized programs: Oncology, Thalassemia, Hemostasis and Thrombosis, and Platelet disorders. The division also has a robust research and training program.
The pediatric cancer program is in a phase of rapid growth. Its new Adolescent and Young Adult Program, headed by Lisa Roth, M.D., is a collaborative effort of the departments of Medicine and Pediatrics to address the unique needs of the underserved 18-30-year-old patient population.
Cancer is commonly associated with thrombotic and bleeding complications. The benign hematology service provides consultation for cancer patients with complex thrombotic and bleeding manifestations, and specifically cancer patients with recurrent venous thrombosis in spite of anticoagulant therapy. We have recognized expertise in thrombophilia, platelet disorders, anemia and bleeding disorders.
Our internationally known center of excellence provides a comprehensive approach for patients with cancer and blood diseases in need of stem cell transplant. Services include autologous and allogeneic bone marrow and peripheral blood stem cell transplantation, cord blood transplantation, matched unrelated donor stem cell transplantation, and non-ablative "mini" transplants.